Stockscreener 앱 받기
24.77
6.22%
1.46
전일 마감가:
$23.31
열려 있는:
$23.8
하루 거래량:
461.61K
Relative Volume:
0.63
시가총액:
$1.87B
수익:
$122.87M
순이익/손실:
$-73.68M
주가수익비율:
-25.27
EPS:
-0.9803
순현금흐름:
$-39.27M
1주 성능:
+4.78%
1개월 성능:
+5.63%
6개월 성능:
+75.11%
1년 성능:
+94.35%
1일 변동 폭
$23.32
$24.80
1주일 범위
$22.26
$24.80
52주 변동 폭
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
명칭
Zymeworks Inc.
전화
604-678-1388
주소
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
24.75 | 1.76B | 122.87M | -73.68M | -39.27M | -0.9803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.86 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.31 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
753.63 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.79 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-10-24 | 재개 | Wells Fargo | Equal Weight |
| 2025-10-14 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | TD Cowen | Buy |
| 2024-12-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-07 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 재개 | Wells Fargo | Overweight |
| 2023-01-04 | 재확인 | H.C. Wainwright | Neutral |
| 2022-12-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
| 2022-05-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-03-15 | 개시 | Evercore ISI | Outperform |
| 2021-12-10 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 재개 | Guggenheim | Neutral |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-02-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 재개 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-08-06 | 개시 | SVB Leerink | Outperform |
| 2020-01-10 | 개시 | Wolfe Research | Outperform |
| 2019-12-09 | 개시 | JP Morgan | Neutral |
| 2019-11-25 | 개시 | H.C. Wainwright | Buy |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-30 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 개시 | Stifel | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 개시 | Raymond James | Outperform |
모두보기
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
Stifel raises Zymeworks stock price target on royalty deal value - Investing.com
Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript - Insider Monkey
Citizens reiterates Zymeworks stock rating on strong cash position By Investing.com - Investing.com Canada
Decoding Zymeworks Inc (ZYME): A Strategic SWOT Insight - GuruFocus
Zymeworks (ZYME) Advances with Promising Zanidatamab Results - GuruFocus
Zymeworks (ZYME) Reveals Q4 Revenue Drop and Strategic Focus Shi - GuruFocus
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience - GuruFocus
Jefferies reiterates Zymeworks stock rating on financing deal - Investing.com
Zymeworks Secures $250 Million Non-Dilutive Royalty-Backed Financing from Royalty Pharma for Ziihera Royalties - Minichart
Zymeworks Inc. (ZYME) Posts Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz
Earnings call transcript: Zymeworks Q4 2025 shows revenue growth, net loss reduction - Investing.com UK
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens - AlphaStreet News
Zymeworks Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
Zymeworks Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ZYME) 2026-03-02 - Seeking Alpha
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript - AOL.com
Zymeworks Monetizes Ziihera Royalties to Boost Liquidity - TipRanks
Zymeworks Posts Strong 2025 Growth and Bolsters Liquidity - TipRanks
Zymeworks 2025 10-K: $106M Revenue, $(1.08) EPS - TradingView
Zymeworks Inc. Q4 Loss Widens - Nasdaq
Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing - Stock Titan
Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma - Nasdaq
Zymeworks Inc. Reports Financial Results for 2025 and Updates on Ziihera® Development and Strategic Plans - Quiver Quantitative
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - GlobeNewswire
Aug Levels: How sensitive is Zymeworks Inc to inflationMarket Sentiment Review & Verified Short-Term Trading Plans - baoquankhu1.vn
A Look Ahead: Zymeworks's Earnings Forecast - Benzinga
Zymeworks Inc. (ZYME) Stock Analysis: A High Upside Prospect with Promising Biotech Innovations - DirectorsTalk Interviews
Zymeworks Inc. (ZYME) Stock Analysis: Biotech Innovator With 56% Potential Upside - DirectorsTalk Interviews
Does Zymeworks Inc stock have upside surprise potential2025 Market Sentiment & Accurate Intraday Trade Tips - baoquankhu1.vn
Zymeworks (ZYME) Form 144 shows insider sell request of 31,641 shares - Stock Titan
How Zymeworks Inc. (ZYME) Affects Rotational Strategy Timing - Stock Traders Daily
How Zymeworks Inc. stock valuations compare to rivalsTrade Exit Summary & Long-Term Capital Growth Ideas - mfd.ru
What is Zymeworks Inc.’s TAM (Total Addressable Market)Long Setup & Precise Buy Zone Identification - mfd.ru
Zymeworks Inc. (ZYME) Stock Analysis: A Biotech Gem With 57% Potential Upside - DirectorsTalk Interviews
Should I average down on Zymeworks Inc. stockJuly 2025 Retail & Low Risk Entry Point Tips - mfd.ru
Is Zymeworks Inc.’s ROE strong enough2025 Short Interest & Precise Trade Entry Recommendations - mfd.ru
Zymeworks Sets Date for 2025 Results and Corporate Update - TipRanks
Zymeworks Inc. Scheduled to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 - GlobeNewswire
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes - MSN
Why Zymeworks Inc. (ZA8) stock is upgraded to buyJuly 2025 Highlights & Daily Price Action Insights - mfd.ru
Zymeworks (NASDAQ:ZYME) Trading 1.2% HigherTime to Buy? - MarketBeat
Aug PreEarnings: What is the dividend yield of AKOBMarket Activity Recap & Verified Stock Trade Ideas - baoquankhu1.vn
Zymeworks (ZYME): Biotech under pressure as investors wait for the next big catalyst - AD HOC NEWS
Tejara Capital Ltd Has $1.46 Million Stock Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Zymeworks Inc. (ZYME): Investor Outlook On A Promising Biotech With 59% Upside Potential - DirectorsTalk Interviews
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge - MSN
Zymeworks Inc. (ZYME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.19%
0.35%
자본화:
|
볼륨(24시간):